After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

AbbVie’s promising pipeline and 3.95% dividend yield offer growth potential. Read why ABBV stock could thrive despite the Emraclidine trial failure.

For the first time, pharmacists in the US will be able to substitute a cheaper biosimilar version when they receive a prescription for AbbVie’s high-concentration formulation of Humira ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

ABBV stock has seen strong gains of 85% from levels of $90 in early January 2021 to around $165 now, vs. an increase of about ...

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...

While Humira's erosion remains a concern, AbbVie has successfully positioned itself for ... The diversity of AbbVie's pipeline across multiple therapeutic areas reduces risk and provides multiple ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

Earlier this month, the S&P 500 hit a record high of more than 6,000 for the first time ever. Based on that, you might assume ...

It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. Humira heir Skyrizi has been slowly creeping up ...